0 401

Cited 1 times in

Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author김윤아-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이재승-
dc.contributor.author이혜원-
dc.date.accessioned2023-03-22T02:04:07Z-
dc.date.available2023-03-22T02:04:07Z-
dc.date.issued2023-02-
dc.identifier.issn0954-691X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/193516-
dc.description.abstractBackground and aim: An optimal sequential anti-hepatocellular carcinoma (HCC) agent that can be used after failed lenvatinib treatment has not been established. Here, we compared the outcomes of sorafenib and nivolumab as second-line agents after failed lenvatinib treatment in patients with advanced HCC. Methods: Patients with advanced HCC who had received sorafenib or nivolumab as second-line agents after failed lenvatinib treatment were recruited from two Korean tertiary institutions between November 2018 and June 2020. Results: The median age of the 60 participants (52 treated with sorafenib and eight treated with nivolumab) at baseline was 56.8 years. The demographic, laboratory and tumor variables, as well as lenvatinib treatment duration, were similar between the two groups. The median durations of sorafenib and nivolumab treatment were 1.2 and 2.6 months, respectively ( P = 0.164). Twenty-four (40.0%) patients died during the follow-up period (median, 15.8 months). The median overall survival (OS) of the study population was 5.8 months. The median OS of patients treated with sorafenib was significantly longer than the median OS of patients treated with nivolumab (8.7 vs. 3.0 months; P = 0.046). Sorafenib treatment (vs. nivolumab) was independently associated with a lower risk of mortality (hazard ratio = 0.194; 95% confidence interval, 0.053-0.708; P = 0.013). Worse Eastern Cooperative Oncology Group performance status, larger maximal tumor size, lymph node metastases and higher total bilirubin levels were independently associated with increased mortality risk (all P < 0.05). Conclusions: Lenvatinib-sorafenib sequential treatment resulted in significantly better survival did than lenvatinib-nivolumab sequential treatment in patients with advanced HCC. Larger studies are needed to validate our results.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLippincott Williams And Wilkins-
dc.relation.isPartOfEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntineoplastic Agents* / adverse effects-
dc.subject.MESHCarcinoma, Hepatocellular* / pathology-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms* / pathology-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNivolumab / adverse effects-
dc.subject.MESHPhenylurea Compounds / adverse effects-
dc.subject.MESHSorafenib / adverse effects-
dc.subject.MESHTreatment Failure-
dc.titleSorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYuna Kim-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorMyung Ji Goh-
dc.contributor.googleauthorWonseok Kang-
dc.contributor.googleauthorSeung Up Kim -
dc.identifier.doi10.1097/MEG.0000000000002466-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA06043-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA05963-
dc.contributor.localIdA03318-
dc.relation.journalcodeJ00821-
dc.identifier.eissn1473-5687-
dc.identifier.pmid36574310-
dc.identifier.urlhttps://journals.lww.com/eurojgh/Fulltext/2023/02000/Sorafenib_versus_nivolumab_after_lenvatinib.7.aspx-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김윤아-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이재승-
dc.contributor.affiliatedAuthor이혜원-
dc.citation.volume35-
dc.citation.number2-
dc.citation.startPage191-
dc.citation.endPage197-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol.35(2) : 191-197, 2023-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.